In New Orleans, the theme song “The Saints Go Marching In,” sings the famous line, “I want to be in that Number.” The American Academy of Ophthalmology is hoping that thousands of its members will want to be in that number too-the Intelligent Research in Sight (IRIS) Registry, formally introduced on Sunday.
Before Paul Sternberg Jr., MD, steps aside from his role as the American Academy of Ophthalmology’s president, he said he does not look back to recount his time in the office. Instead, he addressed the future.
Calling it an “innovator’s dilemma,” Mark S. Blumenkranz, MD, reflected on the extreme difficulties inventors often face in the beginning of a technological advance.
A corneal inlay (Kamra, AcuFocus) for presbyopia seems to be a good treatment option for emmetropic and ametropic presbyopic patients, as well as for presbyopic patients who underwent a previous LASIK procedure, said Minoru Tomita, MD, PhD.
Part-time patching resulted in only a mild reduction in deterioration of intermittent exotropia (IXT), according to Brian G. Mohney, MD.
Findings from an international trial with follow-up in some subjects now extending beyond 6 years show that a retinal prosthesis (Argus II Retinal Prosthesis System, Second Sight Medical Products) remains safe, said Allen C. Ho, MD.
The Affordable Care Act (ACA) has clouded the future of ophthalmology, said William L. Rich, MD.
Looking to the future of dry eye management, Penny Asbell, MD, said she sees multiple examples of hope: a new device, trial findings, and emerging FDA and non-FDA approved therapeutics.
When asking the question, “What’s the ideal surface ablation: Laser, scraping, or alcohol?” it is not surprising that the response from Marguerite B. McDonald, MD, favors an approach known as Epi-Bowman Keratectomy (EBK).
Though fluoroquinolones remain mainstays for treating infectious keratitis, new medical therapies are emerging, said Eduardo C. Alfonso, MD.
The reality of glaucomatous progression bites, said Joel S. Schuman, MD-and it can bite even before structural or functional change is clinically noted by current technology.
When mild glaucoma and a visually significant cataract are both present, the risk/benefit calculus now seems to fall on the side of doing phaco, or a phaco-plus procedure, said James D. Brandt, MD.
You have to walk away from an OIS meeting like this and tell yourself how amazing it is to have great minds developing devices and drugs that will elevate clinical care for ophthalmic patients-and at the end of the day will make physicians’ job easier and better.
Apoptosis may be the best characterized form of programmed cell death-but it isn’t in isolation, said Joan W. Miller, MD.
Often forgotten in the buzz over corneal crosslinking (CXL) is that the procedure kills cells down to 300 µm deep, knocking out everything in its path, including microorganisms and keratocytes, said Theo Seiler, MD, PhD.
For patients with low to moderate hyperopia who may be risk-adverse for surgical correction, there is a low-cost, non-invasive, pain-free procedure of 2.5 seconds, said James J. Salz, MD.
Outcomes for three presbyopia-correcting IOLs-one accommodating and two multifocals-were similar, said Robert Edward Ang, MD.
An update is provided on the latest developments for an evidence-based approach in mild to severe dry eye disease.
Since dry eye is an early presenting sign, eye-care providers need to maintain a high index of suspicion for Sjögren’s syndrome in patients with clinically significant dry eye.
A patient satisfaction and quality-of-life survey found that three presbyopia-correcting IOLs provide better spectacle independence than monovision.
The majority of cataract patients likely have significant tear film disturbances that can affect their preoperative measurements and postoperative satisfaction with cataract surgery.
The absence of glistening formation is among the advantages associated with new IOL technology, relates one ophthalmologist.
Using recent history as a guide, will Medicare cut physician payments by 24% in 2014?
It is not too early for members of the vision science community to make plans for the 2014 meeting of the Association for Research in Vision and Ophthalmology (ARVO).
In my own personal experience, there have always been infections that are difficult to treat (e.g., acanthamoeba or fungal keratitis), but that was no less the case 20 years ago than it is today. Bacterial infections are not (in my humble opinion) particularly more a concern today than they were a decade or two ago.
Maintenance is an important determinant for the efficacy of any intervention
New diagnostic platforms for dry eye disease can help in determining the underlying cause and severity, which is useful for guiding treatment decisions.
Allegro Ophthalmics LLC has announced the start of a phase II study of ALG-1001 in patients with vitreomacular traction (VMT).
Children born extremely prematurely have up to a 19-times greater risk of retinal detachment later in life than those born at term, according to a Swedish study published this month in Ophthalmology, the journal of the American Academy of Ophthalmology.
OD-OS has announced that its Navilas laser has been selected for a new study to evaluate the efficacy and stability of laser plus anti-vascular endothelial growth factor for the treatment of patients with diabetic macular edema (DME).
